Kanwal P.S. Raghav, MBBS, MD

Peer-Reviewed Articles

1. Pattalachinti, V, Haque, E, Yousef, M, Yousef, A, Chowdhury, S, Overman, MJ, Parseghian, C, Morris, VK, Kee, BK, Huey, RW, Raghav, KS, Court, CM, Shen, JY. BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. npj Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 39910160.
2. White, MG, Zeineddine, MA, Fallon, EA, Zeineddine, F, Dansby, J, Chowdhury, S, Hornstein, N, Yousef, A, Yousef, M, Bhutiani, N, Gu, Y, Kee, BK, Dasari, NV, Overman, MJ, Raghav, KS, Kopetz, S, Uppal, A, Taggart, MW, Newhook, TE, Fournier, KF, Helmink, BA, Drusbosky, L, Shen, JY. The Landscape of ctDNA in Appendiceal Adenocarcinoma. Clinical Cancer Research 31(3):551-560, 2025. e-Pub 2025. PMID: 39679931.
3. Piha-Paul, SA, Tseng, C, Tran, HT, Naing, A, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Yap, TA, Raghav, KS, Damodaran, S, Le, X, Soliman, PT, Lim, J, Meric-Bernstam, F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2), 2025. e-Pub 2025. PMID: 39908697.
4. Raghav KPS, Guthrie KA, Tan B Jr, Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS, Esparaz BT, Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean EG, Kopetz S, Hochster HS, Philip PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial. J Clin Oncol 43(11):JCO2401710, 2025. e-Pub 2025. PMID: 39761503.
5. Yennu, S, Valero, V, Smalgo, BG, Overman, MJ, Dasari, A, Wolff, RA, Raghav, KS, Barcenas, CH, Busaidy, NL, Fellman, B, Basen-Engquist, KM, Hess, KR, Tripathy, D, Bruera, E. Physical Activity and Dexamethasone for Cancer-Related Fatigue. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39773433.
6. Strickler, JH, Bekaii-Saab, T, Cercek, A, Heinemann, V, Nakamura, Y, Raghav, KS, Siena, S, Tabernero, J, Van Cutsem, E, Yoshino, T, Ramos, J, Guan, X, Andre, T. MOUNTAINEER-03 phase III study design. Future Oncology 21(3):303-311, 2025. e-Pub 2025. PMID: 39723627.
7. Siena, S, Raghav, KS, Masuishi, T, Yamaguchi, K, Nishina, T, Elez, E, Rodríguez, J, Chau, I, Di Bartolomeo, M, Kawakami, H, Suto, F, Koga, M, Inaki, K, Kuwahara, Y, Takehara, I, Barrios, D, Kobayashi, K, Grothey, A, Yoshino, T. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer. Nature communications 15(1), 2024. e-Pub 2024. PMID: 39587050.
8. Yousef, M, Yousef, A, Chowdhury, S, Fanaeian, M, Knafl, M, Peterson, J, Zeineddine, MA, Alfaro, KD, Zeineddine, F, Goldstein, D, Hornstein, N, Dasari, NV, Huey, RW, Johnson, B, Serpas Higbie, V, Bent, AH, Kee, BK, Lee, MS, Morelli, MP, Morris, VK, Halperin, DM, Overman, MJ, Parseghian, C, Vilar Sanchez, E, Wolff, RA, Raghav, KS, White, MG, Uppal, A, Sun, R, Wang, W, Kopetz, S, Willis, JA, Shen, JY. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncology 10(11), 2024. e-Pub 2024. PMID: 39264607.
9. Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, Andre T, Lonardi S, Yamaguchi K, Tie J, Castro CG, Hsu HC, Strickler JH, Kim TY, Cha Y, Barrios D, Yan Q, Kamio T, Kobayashi K, Boran A, Koga M, Allard JD, Yoshino T. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 25(9):1147-1162, 2024. e-Pub 2024. PMID: 39116902.
10. Piha-Paul SA, Tseng C, Leung CH, Yuan Y, Karp DD, Subbiah V, Hong D, Fu S, Naing A, Rodon J, Javle M, Ajani JA, Raghav KP, Somaiah N, Mills GB, Tsimberidou AM, Zheng X, Chen K, Meric-Bernstam F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol 8(1):166, 2024. e-Pub 2024. PMID: 39085400.
11. Hornstein NJ, Zeineddine MA, Gunes BB, Pellatt AJ, Knafl M, Zhu H, Willett AF, Yousef A, Liu S, Sun R, Futreal A, Woodman SE, Taggart MW, Overman MJ, Halperin DM, Raghav KP, Shen JP. Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma. Cancer Res Commun 4(5):1363-1368, 2024. e-Pub 2024. PMID: 38709066.
12. Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. Oncologist 29(4):e514-e525, 2024. e-Pub 2024. PMID: 38297981.
13. Johnson B, Morris V, Wang X, Dasari A, Raghav K, Shen JP, Lee MS, Huey R, Parseghian C, Willis J, Wolff R, Drusbosky LM, Overman MJ, Kopetz S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel) 16(4), 2024. e-Pub 2024. PMID: 38398128.
14. Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open 7(2):e240260, 2024. e-Pub 2024. PMID: 38416491.
15. Raghav KPS, Loree JM, Kopetz S. PRESSING need of precision care in HER2-positive CRC: The ELEPHANT in the room. Clin Cancer Res 30(2):260-262, 2024. e-Pub 2024. PMID: 37975903.
16. Bhutiani, N, Grotz, TE, Concors, SJ, White, MG, Helmink, BA, Raghav, KS, Taggart, MW, Beaty, K, Royal, RE, Overman, MJ, Matamoros Jr, A, Scally, CP, Rafeeq, S, Mansfield, PF, Fournier, KF. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma. Annals of surgical oncology 31(1):614-621, 2024. e-Pub 2024. PMID: 37872456.
17. Simmons, K, Thomas, J, Ludford, K, Willis, JA, Serpas Higbie, V, Raghav, KS, Johnson, B, Dasari, NV, Kee, BK, Parseghian, C, Lee, MS, Le, PH, Morelli, MP, Shen, JY, Bent, AH, Vilar Sanchez, E, Wolff, RA, Kopetz, S, Overman, MJ, Morris, VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
18. Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Wainberg Z, Elez E, Rodriguez J, Fakih M, Ciardiello F, Saxena K, Kobayashi K, Bako E, Okuda Y, Meinhardt G, Grothey A, Siena S, investigators D. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 14(1):3332, 2023. e-Pub 2023. PMID: 37286557.
19. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
20. Erstad DJ, Robinson KA, Beaty K, Rafeeq S, Chiang YJ, Raghav K, Shen JP, Overman MJ, Foo WC, Taggart MW, Mansfield PF, Royal RE, Fournier KF, Scally CP. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbeck's Archives of Surgery 408(1):110, 2023. e-Pub 2023. PMID: 36853519.
21. Kolbinger FR, Bernard V, Lee JJ, Stephens BM, Branchi V, Raghav KPS, Maitra A, Guerrero PA, Semaan A. Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. J Gastrointest Cancer 54(4):1276-1285, 2023. e-Pub 2023. PMID: 36862364.
22. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun 3(12):2510-2517, 2023. e-Pub 2023. PMID: 38085001.
23. Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer 194:113356, 2023. e-Pub 2023. PMID: 37827065.
24. Neal Bhutiani MD, PhD, Travis E Grotz MD, Seth J Concors MD, Michael G White MD, MSc, Beth A Helmink MD, PhD, Raghav MBBS KP, MD, Melissa W Taggart MD, Beaty PA-C KA, Richard E Royal MD, Michael J Overman MD, Aurelio Matamoros MD, Christopher P Scally MD, MS, Safia Rafeeq MD, Paul F Mansfield MD, Keith F Fournier MD. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol, 2023. e-Pub 2023.
25. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol 7:e2300228, 2023. e-Pub 2023. PMID: 37824798.
26. Yousef A, Yousef M, Zeineddine M, More A, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine F, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally C, Kee B, Kopetz S, Goldstein D, Uppal A, White MG, Helmink B, Fournier K, Raghav K, Taggart M, Overman MJ, Shen JP. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma. medRxiv, 2023. e-Pub 2023. PMID: 37745596.
27. Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo B, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and Value of Genomic-Profiling in Cancer of Unknown Primary: Real-World Evidence from Prospective Profiling Study. J Natl Cancer Inst 115(8):994-997, 2023. e-Pub 2023. PMID: 37202363.
28. De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, Abi Jaoude J, Corrigan KL, Manzar GS, Marqueen KE, Bernard V, Lee SS, Raghav KPS, Vauthey JN, Tzeng CD, Tran Cao HS, Lee G, Wo JY, Hong TS, Crane CH, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer 12(3):198-208, 2023. e-Pub 2023. PMID: 37593365.
29. Shen JP, Yousef AM, Zeineddine FA, Zeineddine MA, Tidwell RS, Beaty KA, Scofield LC, Rafeeq S, Hornstein N, Lano E, Eng C, Matamoros A, Foo WC, Uppal A, Scally C, Mansfield P, Taggart M, Raghav KP, Overman MJ, Fournier K. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open 6(6):e2316161, 2023. e-Pub 2023. PMID: 37261831.
30. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg 277(5):813-820, 2023. e-Pub 2023. PMID: 35797554.
31. Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, Beck EJ, Taniguchi CM, Minsky BD, Fuller CD, Lee JJ, Kupferman M, Raghav KP, Overman MJ, Thomas CR, Ludmir EB. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open 6(5):e2313819, 2023. e-Pub 2023. PMID: 37195664.
32. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol 41(12):JCO2201351, 2023. e-Pub 2023. PMID: 36623241.
33. Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, Cosgrove D, Fiorillo JA, Tam R, D'Adamo D, Sharma N, Brennan BJ, Wang YA, Coppieters S, Zebger-Gong H, Weispfenning A, Seidel H, Ploeger BA, Mueller U, Oliveira CSV, Paulson AS. Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study. EClinicalMedicine 58:101917, 2023. e-Pub 2023. PMID: 37090438.
34. Parseghian CM, Sun R, Woods M, Napolitano S, Lee HM, Alshenaifi J, Willis J, Nunez S, Raghav KP, Morris VK, Shen JP, Eluri M, Sorokin A, Kanikarla P, Vilar E, Rehn M, Ang A, Troiani T, Kopetz S. Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen and Line of Therapy. J Clin Oncol 41(3):101200JCO2201423, 2023. e-Pub 2023. PMID: 36351210.
35. Raghav K, Ou FS, Venook AP, Innocenti F, Sun R, Lenz HJ, Kopetz S. Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance). J Clin Oncol 41(3):JCO2200365, 2023. e-Pub 2023. PMID: 36067452.
36. Parseghian C, Eluri M, Kopetz S, Raghav K. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Front Cell Dev Biol 11:1176657, 2023. e-Pub 2023. PMID: 37791069.
37. Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol 23(12):1558-1570, 2022. e-Pub 2022. PMID: 36400106.
38. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. e-Pub 2022. PMID: 35946836.
39. Malpica A, Euscher ED, Marques-Piubelli ML, Miranda RN, Raghav KP, Fournier KF, Ramalingam P. Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases. Am J Surg Pathol 46(10):1352-1363, 2022. e-Pub 2022. PMID: 35713639.
40. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open 5(10):e2236357, 2022. e-Pub 2022. PMID: 36239938.
41. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
42. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 10(8), 2022. e-Pub 2022. PMID: 36007963.
43. De B, Tran Cao HS, Vauthey JN, Manzar GS, Corrigan KL, Raghav KPS, Lee SS, Tzeng CD, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer 128(13):2529-2539, 2022. e-Pub 2022. PMID: 35417569.
44. Lee S, Shroff RT, Makawita S, Xiao L, Danner De Armas A, Bhosale P, Reddy K, Shalaby A, Raghav K, Pant S, Wolff RA, Javle M. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy. Clin Cancer Res 28(11):2229-2236, 2022. e-Pub 2022. PMID: 35312753.
45. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5(5):e2213588, 2022. e-Pub 2022. PMID: 35608860.
46. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. e-Pub 2022. PMID: 35618285.
47. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. e-Pub 2022. PMID: 35557581.
48. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2022. PMID: 34794903.
49. Malpica A, Euscher ED, Marques-Piubelli ML, Miranda RN, Fournier KF, Raghav KP, Ramalingam P. Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases. Int J Gynecol Pathol 41(1):59-67, 2022. e-Pub 2022. PMID: 33577225.
50. Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
51. De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 11(12), 2021. e-Pub 2021. PMID: 34945742.
52. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
53. Raghav, KS, Wainberg, ZA, Bekaii-Saab, T. Quality-of-life concerns in patients with metastatic colorectal cancer. Clinical Advances in Hematology and Oncology 19(10):1-14, 2021. e-Pub 2021.
54. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol 12(5):2268-2274, 2021. e-Pub 2021. PMID: 34790391.
55. Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open 4(8):e2119934, 2021. e-Pub 2021. PMID: 34357397.
56. Raghav K, Anand S, Gothwal A, Singh P, Dasari A, Overman MJ, Loree JM. Underreporting of race/ethnicity in COVID-19 research. Int J Infect Dis 108:419-421, 2021. e-Pub 2021. PMID: 34087489.
57. Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clin Cancer Res 27(12):3414-3421, 2021. e-Pub 2021. PMID: 33858857.
58. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res 27(11):3039-3049, 2021. e-Pub 2021. PMID: 33811152.
59. Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, Yamaguchi K, Nishina T, Fakih M, Elez E, Rodriguez J, Ciardiello F, Komatsu Y, Esaki T, Chung K, Wainberg Z, Sartore-Bianchi A, Saxena K, Yamamoto E, Bako E, Okuda Y, Shahidi J, Grothey A, Yoshino T, investigators D. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 22(6):779-789, 2021. e-Pub 2021. PMID: 33961795.
60. Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk. Hepatology 73(6):2278-2292, 2021. e-Pub 2021. PMID: 32931023.
61. Bhamidipati D, Colina A, Hwang H, Wang H, Katz M, Fournier K, Serpas V, Thomas J, Sun R, Wolff RA, Raghav K, Overman MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open 6(3):100132, 2021. e-Pub 2021. PMID: 33940348.
62. Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist 26(4):e650-e657, 2021. e-Pub 2021. PMID: 33524217.
63. Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 39(4):285-294, 2021. e-Pub 2021. PMID: 33356422.
64. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist 26(2):107-114, 2021. e-Pub 2021. PMID: 32960478.
65. Loree JM, Dau H, Rebic N, Howren A, Gastonguay L, McTaggart-Cowan H, Gill S, Raghav K, De Vera MA. Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. Curr Oncol 28(1):671-677, 2021. e-Pub 2021. PMID: 33499380.
66. Malpica A, Euscher ED, Marques-Piubelli ML, Ferrufino-Schmidt MC, Miranda RN, Sams R, Royal RE, Raghav KPS, Fournier KF, Ramalingam P. Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Am J Surg Pathol 45(1):45-58, 2021. e-Pub 2021. PMID: 32769428.
67. De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma 8:57-69, 2021. e-Pub 2021. PMID: 33688489.
68. Chen AP, Kummar S, Moore N, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Sims D, O'Sullivan Coyne G, Rosenberger CL, Simpson M, Raghav KPS, Meric-Bernstam F, Leong S, Waqar S, Foster JC, Konaté MM, Das B, Karlovich C, Lih CJ, Polley E, Simon R, Li MC, Piekarz R, Doroshow JH. Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial. JCO Precis Oncol 5(5):133-144, 2021. e-Pub 2021. PMID: 33928209.
69. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5:613-621, 2021. e-Pub 2021. PMID: 34250391.
70. Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 8:1129-1145, 2021. e-Pub 2021. PMID: 34527608.
71. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
72. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer 19(4):248-255.e6, 2020. e-Pub 2020. PMID: 32665092.
73. Fujii S, Magliocco AM, Kim J, Okamoto W, Kim JE, Sawada K, Nakamura Y, Kopetz S, Park WY, Tsuchihara K, Kim TW, Raghav K, Yoshino T. International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel. JCO Precis Oncol 4:6-19, 2020. e-Pub 2020. PMID: 35050726.
74. Raghav K, Overman M, Poage GM, Soifer HS, Schnabel CA, Varadhachary GR. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist 25(11):e1807-e1811, 2020. e-Pub 2020. PMID: 32893931.
75. Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open 5(6):e000960, 2020. e-Pub 2020. PMID: 33188051.
76. Raghav K, Shen JP, Jácome AA, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer 123(8):1262-1270, 2020. e-Pub 2020. PMID: 32733093.
77. Zhao Y, Pan Z, Namburi S, Pattison A, Posner A, Balachander S, Paisie CA, Reddi HV, Rueter J, Gill AJ, Fox S, Raghav KPS, Flynn WF, Tothill RW, Li S, Karuturi RKM, George J. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine 61:103030. e-Pub 2020. PMID: 33039710.
78. Chu JE, Johnson B, Kugathasan L, Morris VK, Raghav K, Swanson L, Lim HJ, Renouf DJ, Gill S, Wolber R, Karsan A, Kopetz S, Schaeffer DF, Loree JM. Population-based screening for BRAFV600E in metastatic colorectal cancer reveals increased prevalence and poor prognosis. Clin Cancer Res 26(17):4599-4605, 2020. e-Pub 2020. PMID: 32571791.
79. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med 9(15):5406-5415, 2020. e-Pub 2020. PMID: 32519420.
80. Unger JM, Hershman DL, Osarogiagbon RU, Gothwal A, Anand S, Dasari A, Overman M, Loree JM, Raghav K. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectr 4(4):pkaa034, 2020. e-Pub 2020. PMID: 32704619.
81. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology 20(3):501-504, 2020. e-Pub 2020. PMID: 31932214.
82. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32188704.
83. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer 19(1):48-56.e2, 2020. e-Pub 2020. PMID: 32008976.
84. Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology 98(12):1-11, 2020. e-Pub 2020. PMID: 33027788.
85. Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbort M, Chen K, Shaw KRM, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis Oncol 3:1-13, 2019. e-Pub 2019. PMID: 35100667.
86. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
87. Pedersen KS, Raghav K, Overman MJ. Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. J Natl Compr Canc Netw 17(9):1135-1141, 2019. e-Pub 2019. PMID: 31487680.
88. Raghav K, Strickler JH. The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. JAMA Oncol. e-Pub 2019. PMID: 31415062.
89. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol:e191870. e-Pub 2019. PMID: 31415071.
90. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. e-Pub 2019. PMID: 31406299.
91. Kaseb AO, Sánchez NS, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. e-Pub 2019. PMID: 31363003.
92. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol 5(6):824-830, 2019. e-Pub 2019. PMID: 30998813.
93. Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, Trusolino L, Marsoni S, Siena S, Bardelli A. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res 25(10):3046-3053, 2019. e-Pub 2019. PMID: 30808777.
94. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, Murthy RK, Rodon J, Piha-Paul SA. Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. Clin Cancer Res 25(7):2033-2041, 2019. e-Pub 2019. PMID: 30442682.
95. Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 20(4):518-530, 2019. e-Pub 2019. PMID: 30857956.
96. Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 133:54-61, 2019. e-Pub 2019. PMID: 30935582.
97. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. e-Pub 2019. PMID: 30854646.
98. Parseghian CM, Tam AL, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol 5(3):402-405, 2019. e-Pub 2019. PMID: 30383128.
99. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol 30(2):243-249, 2019. e-Pub 2019. PMID: 30462160.
100. Raghav K, Loree JM, Morris JS, Overman MJ, Ruoxi Y, Meric-Bernsatm F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbourt M, Chen K, Shaw KR, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 Amplification as a Predictive Biomarker for Anti–Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precision Oncology, 2019. e-Pub 2019.
101. Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32923865.
102. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914034.
103. Aldrich JD, Raghav KPS, Varadhachary GR, Wolff RA, Overman MJ. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. e-Pub 2018. PMID: 30598498.
104. Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget 9(102):37721-37732, 2018. e-Pub 2018. PMID: 30701027.
105. Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol 18(1):169, 2018. e-Pub 2018. PMID: 30541475.
106. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med 7(10):4880-4892, 2018. e-Pub 2018. PMID: 30152073.
107. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. e-Pub 2018. PMID: 30205948.
108. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
109. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. e-Pub 2018. PMID: 29718453.
110. Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. e-Pub 2018. PMID: 29579338.
111. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2018. PMID: 29180604.
112. Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst. e-Pub 2018. PMID: 29346573.
113. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic R, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2018. PMID: 29069279.
114. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. e-Pub 2017. PMID: 29259073.
115. Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am 26(4):667-687, 2017. e-Pub 2017. PMID: 28923224.
116. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. e-Pub 2017. PMID: 28936799.
117. Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol 24(9):2646-2654, 2017. e-Pub 2017. PMID: 28695394.
118. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. e-Pub 2017. PMID: 28831698.
119. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
120. Parseghian C, Raghav K, Wolff RA, Ensor JE, Yao JC, Ellis LM, Tam A, Overman MJ. Under-reporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. e-Pub 2017. PMID: 28754815.
121. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther 16(7):1435-1442, 2017. e-Pub 2017. PMID: 28468778.
122. Vega EA, Yamashita S, Chun YS, Kim M, Fleming JB, Katz MH, Tzeng CW, Raghav KP, Vauthey JN, Lee JE, Conrad C. Effective Laparoscopic Management Lymph Node Dissection for Gallbladder Cancer. Ann Surg Oncol 24(7):1852, 2017. e-Pub 2017. PMID: 28168387.
123. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. e-Pub 2017. PMID: 28424412.
124. Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, Kaseb A, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol 4:39-45, 2017. e-Pub 2017. PMID: 29594206.
125. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer 123(6):1011-1017, 2017. e-Pub 2017. PMID: 27859010.
126. Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer 17(1):331, 2017. e-Pub 2017. PMID: 28506255.
127. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer 123(8):1354-1362, 2017. e-Pub 2017. PMID: 27984655.
128. Vega EA, Yamashita S, Shin CY, Kim M, Fleming JB, Katz MH, Raghav KP, Vauthey JN, Lee JE, Conrad C. Laparoscopic Partial Splenectomy for Unknown Primary Cancer: A Stepwise Approach. Ann Surg Oncol 24(4):1134, 2017. e-Pub 2017. PMID: 27942901.
129. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol 24(1):187-193, 2017. e-Pub 2017. PMID: 27660258.
130. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One 12(8):e0183949, 2017. e-Pub 2017. PMID: 28850629.
131. Sarshekeh AM, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(3):e0173345, 2017. e-Pub 2017. PMID: 28267766.
132. Korphaisarn K, Chou CK, Xia WY, Clarke CN, Katkhuda R, Davis JS, Raghav KP, Liao HW, Wu JY, Menter DG, Maru DM, Hung MC, Kopetz S. Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment. Am J Cancer Res 7(12):2587-2599, 2017. e-Pub 2017. PMID: 29312811.
133. Yamashita S, Vauthey JN, Kaseb AO, Aloia TA, Conrad C, Hassan MM, Passot G, Raghav KP, Shama MA, Chun YS. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. J Gastrointest Surg 20(10):1725-31, 2016. e-Pub 2016. PMID: 27456016.
134. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. e-Pub 2016. PMID: 27421137.
135. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
136. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. Journal of Hepatocellular Carcinoma 3:1-7, 2016. e-Pub 2016.
137. Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med 5(2):239-47, 2016. e-Pub 2016. PMID: 26714799.
138. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 3:1-7, 2016. e-Pub 2016. PMID: 27574586.
139. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther 9:773-80, 2016. e-Pub 2016. PMID: 26929648.
140. Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One 11(5):e0154985, 2016. e-Pub 2016. PMID: 27171493.
141. Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK. Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction. PLoS One 11(1):e0145534, 2016. e-Pub 2016. PMID: 26752563.
142. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol 33(31):3583-90, 2015. e-Pub 2015. PMID: 26304898.
143. Shah MS, Fogelman DR, Raghav KP, Heymach JV, Tran HT, Jiang ZQ, Kopetz S, Daniel CR. Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer 121(17):2968-75, 2015. e-Pub 2015. PMID: 25975416.
144. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP Scoring System for Assessing Hepatic Reserve in Egyptian Patients with Hepatocellular Carcinoma. Oncotarget 6(25):21193-207, 2015. e-Pub 2015. PMID: 26098859.
145. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology 149(1):119-29, 2015. e-Pub 2015. PMID: 25836985.
146. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088-97, 2015. e-Pub 2015. PMID: 25688736.
147. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 15:713, 2015. e-Pub 2015. PMID: 26474549.
148. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst 106(5), 2014. e-Pub 2014. PMID: 24815863.
149. Raghav K, Overman MJ. Small bowel adenocarcinomas-existing evidence and evolving paradigms. Nat Rev Clin Oncol 10(9):534-44, 2013. e-Pub 2013. PMID: 23897080.
150. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 18(12):1270-7, 2013. e-Pub 2013. PMID: 24149137.
151. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res 1(3):179-93, 2012. e-Pub 2012. PMID: 25806180.
152. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
153. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Macgregor M, Meric-Bernstam F, Buchholz TA, Sahin A, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer 118(6):1498-506, 2012. e-Pub 2012. PMID: 21837669.
154. Raghav KP, Makkuni P, Figueredo VM. A review of electrocardiography in pulmonary embolism: recognizing pulmonary embolus masquerading as ST-elevation myocardial infarction. Rev Cardiovasc Med 12(3):157-63, 2011. e-Pub 2011. PMID: 22145193.

Invited Articles

1. Raghav KPS, Moasser MM. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy. Clin Cancer Res 29(13):2351-2361, 2023. e-Pub 2023. PMID: 36574481.
2. Fangman B, Raghav K, Kopetz S. Circulating Tumor DNA as a Marker of Minimal Residual Disease. Oncology (Williston Park) 36(10):600-603, 2022. e-Pub 2022. PMID: 36260787.
3. Raghav KP. Sequencing strategies in the management of metastatic colorectal cancer with HER2 amplification. Clin Adv Hematol Oncol 20(2):86-88, 2022. e-Pub 2022. PMID: 35120088.
4. Bekaii-Saab TS, Raghav K, Wainberg ZA. How quality of life can inform management decisions in later-line metastatic colorectal cancer: Q&A. Clin Adv Hematol Oncol 19 Suppl 22(10):13-14, 2021. e-Pub 2021. PMID: 35289806.
5. Raghav K. Quality-of-life concerns in patients with metastatic colorectal cancer. Clin Adv Hematol Oncol 22(10):2-6, 2021. e-Pub 2021. PMID: 35289803.
6. Bekaii-Saab TS, Raghav K, Wainberg ZA. How quality of life can inform management decisions in later-line metastatic colorectal cancer. Clin Adv Hematol Oncol 22(10):1-16, 2021. e-Pub 2021. PMID: 35289802.
7. Raghav KPS. The role of HER2 amplification testing in metastatic colorectal cancer. Clin Adv Hematol Oncol 16(11):720-722, 2018. e-Pub 2018. PMID: 30543586.
8. Loree JM, Kopetz S, Raghav KP. Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. J Gastrointest Oncol 8(1):199-212, 2017. e-Pub 2017. PMID: 28280626.
9. Raghav K, Eng C. Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer. American Journal of Hematology/Oncology 11(7), 2015. e-Pub 2015.
10. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Translational Lung Cancer Research 1(2):179-193, 2012. e-Pub 2012.
11. Raghav KP, Eng C. Role of MET/HGF Axis in Colorectal Cancer: Precepts and Prospects. Colorectal Cancer 1(4):329-341, 2012. e-Pub 2012.
12. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs 20(6):859-69, 2011. e-Pub 2011. PMID: 21534718.

Manuals, Teaching Aids, Other Teaching Publications

1. Overman MJ, Compton CC, Raghav K. Appendiceal mucinous lesions. UpToDate, 2019.
2. Raghav KP. NEJM Knowledge+. The New England Journal of Medicine, 2014.

Other Articles

1. Siena, S, Raghav, KS, Masuishi, T, Yamaguchi, K, Nishina, T, Elez, E, Rodríguez, J, Chau, I, Di Bartolomeo, M, Kawakami, H, Suto, F, Koga, M, Inaki, K, Kuwahara, Y, Takehara, I, Barrios, D, Kobayashi, K, Grothey, A, Yoshino, T Correction to. Nature communications 16(1), 2025. PMID: 39814812.

Editorials

1. Raghav KP, Gonzalez-Angulo AM. Commentary on: Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Breast Diseases: A Year Book Quarterly 22(2):156-158, 2011.

Abstracts

1. Raghav K, Mody K, Greten TF, Paluri RK, Lee RT, Bonne J BS, Theuer CP, Kaseb AO. An open label phase 1b/2 trial of TRC105 and sorafenib in patient with advanced/metastatic hepatocellular carcinoma (HCC) (NCT01806064). Gastrointestinal Cancer Symposium 2018, 2018. e-Pub 2018.
2. Raghav K, Fournier KF, Johnson, B, Taggart MW, Foo WC, Matamoros Jr A, Mehdizadeh A, Ahmed SU, Guerra JL, Mansfield PF, Royal RE, Eng C, Overman MJ. Interplay of grade and stage on survival outcomes in appendiceal adenocarcinoma: Corroboration of the AJCC (8th edition) Cancer Staging Classification. Gastrointestinal Cancer Symposium 2018, 2018. e-Pub 2018.
3. Raghav K, Loree JM, Fournier KF, Shaw KR, Taggart MW, Foo WC, Matamoros Jr A, Mehdizadeh A, Ahmed SU, Guerra JL, Mansfield PF, Royal RE, Overman MJ, Eng C. Comprehensive genomic profiling of appendiceal adenocarcinoma. Gastrointestinal Cancer Symposium 2018, 2018. e-Pub 2018.
4. Raghav K, Loree JM, Morris J, Manuel S, Crosby S, Meric-Bernstam F, Menter D, Raymond VM, Lanman RB, Talasaz A, Kopetz S. Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC). Gastrointestinal Cancer Symposium 2018, 2018. e-Pub 2018.
5. Hurwitz H, Raghav KPS, Burris H, Kurzrock R, Sweeney C, Meric-Bernstam F, VanderWalde A, Spigel DR, Bose R, Fakih M, Swanton C, Guo S, Yoo B, Beattie M, Sommer N, Hainsworth J. Pertuzumab + Trastuzumab for HER2-Amplified/Overexpressed Metastatic Colorectal Cancer (mCRC): Interim Data from MyPathway. Gastrointestinal Cancer Symposium 2017, 2017. e-Pub 2017.
6. Raghav K, Overman MJ, Yu R, Meric Bernstam F, Menter D, Kee, B, Muranyi A, Singh S, Routbourt M, Chen K, Shaw KR, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. ASCO Annual Meeting 2016, 2016. e-Pub 2016.
7. Raghav KP, Mhadgut H, Lei X, Overman MJ, Ross A, Renato L, Raber M, Varadhacahry GR. Cancer of unknown primary in adolescents and young adults: Clinicopathologic features, prognostic factors, and survival outcomes. ASCO Annual Meeting 2014, 2014. e-Pub 2014.
8. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. ASCO Annual Meeting 2014, 2014. e-Pub 2014.
9. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. ASCO Annual Meeting 2013, 2013. e-Pub 2013.
10. Raghav KP, Amin HM, Wang W, Manyam GC, Broom B, Eng C, Overman MJ, Kopetz S. MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. Gastrointestinal Cancer Symposium 2013, 2013. e-Pub 2013.
11. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. ASCO Annual Meeting 2012, 2012. e-Pub 2012.
12. Raghav KP, Kalil K, Ferrarotto R, George B, Eng C, Garrett C, Loyer EM, Hoff PM, Charnsangavej C, Kopetz S, Overman MJ. Bevacizumab reduces the rate of oxaliplatin induced thrombocytopenia and splenomegaly. Gastrointestinal Cancer Symposium 2012, 2012. e-Pub 2012.
13. Raghav KP, Kazmi SMA, Shetty AV, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Uncovering the clinicopathological and mutational profile of appendiceal adenocarcinomas. Gastrointestinal Cancer Symposium 2012, 2012. e-Pub 2012.
14. Raghav KP, Wang W, Liu S, Chavez-Mac Gregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein Jr GR, Gonzalez-Angulo AM. Expression of cMET and phospho-cMET in breast cancers by subtype and impact on survival outcomes. AACR San Antonio Breast Cancer Symposium 2011, 2011. e-Pub 2011.
15. Raghav KP, Liu DD, Matrana MR, Bekele BN, Valero V, Ibrahim NK. Nomogram for predicting development of brain metastasis in patients with inflammatory breast cancer. ASCO Breast Cancer Symposium 2011, 2011. e-Pub 2011.
16. Raghav KP, Hernandez-Aya LF, Lei X, Chavez-Mac Gregor M, Meric-Bernstam F, Buchholz TA, Sahin AA, Do KA, Hortobagyi GN, Gonzalez-Angulo AM. Impact of low estrogen- and progesterone-receptor expression on survival outcomes in breast cancers previously classified as triple-negative breast cancers. ASCO Annual Meeting 2011, 2011. e-Pub 2011.
17. Raghav KP, Codolosa N, Tester W. Development of second malignancy in a patient with a history of retinoblastoma: A fresh look at the two hit hypothesis. Annual Meeting PA Chapter of ACP 2008, 2008. e-Pub 2008.

Book Chapters

1. Huey, RW, Raghav, KS. Treatment Refractory Metastatic Colorectal Cancer, 287-292, 2022.
2. Raghav K, Abbruzzese J, Varadhachary G. Carcinoma of Unknown Primary. In: Harrison’s Principles of Internal Medicine. 21st, 2022.
3. Raghav KP, Overman MJ. Small Bowel Cancer and Appendiceal Tumors. In: MD Anderson Manual of Medical Oncology. Third. McGraw-Hill Global Education Holdings, LLC, 2015.
4. Raghav KP, Raber M, Varadhachary GR. Cancer of Unknown Primary Site. In: Clinical Decision Support: ONCOLOGY, 2015.
5. Raghav KP, Varadhachary GR. Favorable Subsets Among Cancers of Unknown Primary. In: Textbook of carcinoma of unknown primary. 1. Springer publishing house, 2015.
6. Raghav KP, Gilbert MR. Ependymomas. In: Neuro-oncology. First. Blackwell Publishing Ltd, 86-94, 2012.
7. Raghav KP, Katz MH, Overman MJ. Cancers of the Small Bowel. In: Textbook of Uncommon Cancer. Fourth. John Wiley & Sons, Inc, 4441-451, 2012.

Letters to the Editor

1. Huey, RW, Raghav, KS. Site-specific or empirical chemotherapy for cancer of unknown primary. The lancet oncology 25: e529, 2024.
2. Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. J Clin Oncol 41: JCO2202588, 2023.
3. Bhamidipati D, Anand S, Gothwal A, Raghav K, Overman MJ. On the Underreporting of Health-Related Quality of Life and Regulatory Approval. Ann Oncol 30: 657-658, 2019.
4. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist 20: e3-4, 2015.
5. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity?. J Am Coll Surg 212: 906; author reply 907, 2011.